Agilent Partners with Medication Monitoring Specialist


Agilent Technologies and Ameritox have formed a research collaboration that could accelerate analysis in the field of medication monitoring. “By using multiple Rapid Fire systems Ameritox is streamlining the analysis of small panels of exogenous compounds compared to traditional methods of analysis,” said Can Ozbal, director of Agilent’s Rapid Fire business.


While the RapidFire system has been used extensively in pharmaceutical and biopharmaceutical laboratories, this research collaboration marks one of the first steps by Agilent into medication monitoring with Ameritox, which provides dedicated laboratory testing and reporting services in this field.


“By working together and sharing moment-by-moment laboratory activity, this research arrangement gives both Ameritox and Agilent a vantage point from which we can continue to discover new uses for our science and technology,” said Jay Zimmerman, Chief Laboratory Officer of Ameritox.


“The marriage of Agilent’s technology and Ameritox’s proprietary science could hold the key to major advancements in the field of medication monitoring,” he added.


MORE INFO. 53


Studsvik Issues SEK 200 Million Three Year Bond


Chris Jarvis, Sales & Marketing Manger of International Labmate presents Daniel Scott of Scientific Analysis Laboratories Ltd with the cheque


At International Labmate, we like to keep our readers happy – normally by supplying all the latest news you might need for your laboratory. For one lucky winner however, we’ve gone a little bit further! Last year,


Daniel Scott of Scientific Analysis Laboratories, Wins €500 Labmate Competition


International Labmate gave all new subscribers to any of its laboratory journals the chance to win €500 by entering their names in to a prize draw.


So, when Daniel Scott of Scientific Analysis


Laboratories Ltd received a call to say he’d won the competition, he couldn’t believe his luck and commented: “I don’t ever win anything so this is certainly a pleasant surprise!”


Daniel had subscribed at the Fisher Science World exhibition in London. As ‘Inorganic Section Head’ at SAL Ltd (Manchester UK), one of the largest independent laboratories in Europe, he felt he absolutely needed to be kept up-to-date with all the latest news in the industry, particular as the Company is now analysing and testing samples for the Biological Monitoring and Food & Feeds sectors at a growing rate. He subscribed to International Labmate and certainly got a lot more than he had expected. Congratulations Daniel, enjoy your winnings.


Now it’s your chance to win a Labmate readers competition! For the chance to win an Apple iPad Mini, all you need to do is download the Labmate App (available on Apple and Android devices) and when prompted upon opening the App for the first time, register your details. All subscribers will be entered in to a prize draw to win one of these fantastic gadgets - Good luck!


MORE INFO. 54


Gyros AB Appoints CTO and VP Technical Affairs


Gyros AB, a leader in utilisation of microfluidic technologies to miniaturise and automate immunoassays, has appointed Dr Henrik Björkman as CTO and VP Technical Affairs where he will lead the R&D and product supply teams. He will have responsibility for driving strategic and operational decisions, managing product development, intellectual property, manufacturing, QA, and QC, and overseeing the existing product range. As part of the executive management team Henrik will work closely with marketing and sales departments, reporting to the board of directors.


Henrik joins Gyros from GE Healthcare Life Sciences, where he was most recently Director, MicroCal R&D, leading the MicroCal operation in Northampton, MA. He has many years of experience in senior positions within R&D, technical and management roles, at a range of life science companies from small organisations to larger, industrial enterprises. Henrik holds a PhD in Materials Science and Micro Engineering from Uppsala University.


“The technology developed at Gyros offers an exciting step forward for the biopharmaceutical community,” said Henrik. “I am excited to have the opportunity to support the continued success of the Gyros immunoassay platform.” Erik Walldén, CEO at Gyros, commented: “We welcome Henrik to Gyros, and look forward to working with him. Bringing extensive experience in product development and manufacturing for globalised, commercial organisations in the life science tools industry, Henrik will be a great asset for the continued development of our microfluidic immunoassay technology."


Dr Henrik Björkman MORE INFO. 55 Labwork at Studsvik


On 18 February 2013, Studsvik, a supplier of advanced technical services to the international nuclear power industry in waste treatment, decommissioning, engineering and services, and operating efficiency, announced the decision to investigate the feasibility and conditions of issuing a corporate bond on the Swedish market. Following strong interest the company decided to issue a corporate bond.


The senior unsecured bond, with a volume of SEK 200 million and a final maturity in 2016, has a floating interest rate of STIBOR (3 months) + 3.75 percentage points. Studsvik will apply for listing of the bond on NASDAQ OMX Stockholm.


"We are very pleased by the great interest shown by investors for Studsvik’s bond issue. Through the bond issue we secure a competitive financing for future business opportunities”, commented Jerry Ericsson, CFO Studsvik AB.


Swedbank AB (publ) have acted as financial adviser to Studsvik in connection with the bond issue.


MORE INFO. 56


Varian Medical Systems Supports Integrated Research Programme in Russia


Varian Medical Systems is working with key development agencies in Russia to encourage the country's leading research institutes and scientists to collaborate on research and development proposals for programs aimed at advancing radiotherapy technology.


"The leading technologists within Varian have defined five future development opportunities and will entertain research proposals that address these challenges from scientists in Russia's R&D community," says Scott Johnson, Varian's Senior Manager of research collaborations, who is coordinating Varian's support for the project.


"This is a new type of process for Varian and we are looking forward to supporting forward-thinking, next-generation research that could well be developed and commercialised."


Varian has contributed $50,000 to this venture, which will be combined with other funds equaling $100K in prize money for the team or teams with the best proposals.


The program presents the Russian R&D community with the opportunity to take a focused look at the needs of radiotherapy. "We believe this will yield significant benefits to cancer patients not only in Russia but throughout the world. Russia was the first country to put a man into space and it has a deep, sophisticated technological base in radiation technologies," Johnson says.


The program, which runs over the next six months, is also receiving support from the Skolkovo Foundation, a not-for-profit, government- funded organisation launched in 2010 as part of the Kremlin's efforts to create an innovation ecosystem that is intended as Russia's answer to Silicon Valley.


Varian will assess R&D proposals with the Skolkovo Foundation and the Rusnano Foundation for Infrastructure and Educational Programs (FIEP), which develops and supports Russia's integration with global leaders.


MORE INFO. 57


Read all the latest News & Views, Articles and New Product Releases Online, visit: www.labmate-online.com


Labmate reader competition! See page 53 for further information


Win an iPad Mini in our


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56